ipilimumab,nivolumab
bms
['niche2', 'thank you']
 thank you all for these very good points! hope to continue the debate at #esmo22 and especially looking forward to the #niche2 presentation on sunday!
MD - GI oncology @uzleuven @KU_Leuven